ING Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

ING Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-79,800	Closed	-$2.9M	–	566
2025 Q2	$2.9M	Buy	+79,800	New	+$2.88M	0.02%	308

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

ING Group's RARE Position: Q3 2025 in Review

ING Group sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 79,800 shares — an estimated $2.9M sold.

ING Group first reported a position in RARE in Q2 2025 and held it in 1 quarter. The position peaked at $2.9M in Q2 2025. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

ING Group reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
ING Group sold 79,800 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $2.9M.
ING Group first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 1 quarter.
ING Group's Ultragenyx Pharmaceutical position peaked at $2.9M in Q2 2025.
303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on ING Group's 13F filing for Q3 2025, filed 6 Nov 2025.